elagolix
Modify Date: 2025-08-22 20:10:32
elagolix structure
|
Common Name | elagolix | ||
|---|---|---|---|---|
| CAS Number | 834153-87-6 | Molecular Weight | 631.590 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 728.6±70.0 °C at 760 mmHg | |
| Molecular Formula | C32H30F5N3O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 394.5±35.7 °C | |
Use of elagolixElagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM).Target: GnRHin vitro: Elagolix is a short-acting, nonpeptide, GnRH antagonist, administered orally, that unlike injectable depot GnRH agonists and antagonists, produces a dose-dependent suppression of ovarian estrogen production, that is, from partial suppression at lower doses to full suppression at higher doses. Elagolix is regarded as the frontrunner of a new class of GnRH inhibitors that have been denoted as second-generation, due to their non-peptide nature and oral bioavailability. |
| Name | Elagolix |
|---|---|
| Synonym | More Synonyms |
| Description | Elagolix is a highly potent, selective, orally-active, short-duration, non-peptide antagonist of the gonadotropin-releasing hormone receptor (GnRHR) (KD = 54 pM).Target: GnRHin vitro: Elagolix is a short-acting, nonpeptide, GnRH antagonist, administered orally, that unlike injectable depot GnRH agonists and antagonists, produces a dose-dependent suppression of ovarian estrogen production, that is, from partial suppression at lower doses to full suppression at higher doses. Elagolix is regarded as the frontrunner of a new class of GnRH inhibitors that have been denoted as second-generation, due to their non-peptide nature and oral bioavailability. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 728.6±70.0 °C at 760 mmHg |
| Molecular Formula | C32H30F5N3O5 |
| Molecular Weight | 631.590 |
| Flash Point | 394.5±35.7 °C |
| Exact Mass | 631.210571 |
| PSA | 102.56000 |
| LogP | 7.20 |
| Vapour Pressure | 0.0±2.5 mmHg at 25°C |
| Index of Refraction | 1.567 |
| InChIKey | HEAUOKZIVMZVQL-VWLOTQADSA-N |
| SMILES | COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(CC(NCCCC(=O)O)c3ccccc3)c2=O)c1F |
| Storage condition | 2-8℃ |
|
~91%
elagolix CAS#:834153-87-6 |
| Literature: NEUROCRINE BIOSCIENCES, INC. Patent: WO2009/62087 A1, 2009 ; Location in patent: Page/Page column 17, 18 ; WO 2009/062087 A1 |
|
~%
elagolix CAS#:834153-87-6 |
| Literature: Journal of Medicinal Chemistry, , vol. 51, # 23 p. 7478 - 7485 |
![ethyl (R)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-[2-fluoro-6-(trifluoromethyl)benzyl]-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate structure](https://image.chemsrc.com/caspic/014/832720-84-0.png)
![methyl (R)-4-{2-[5-(2-fluoro-3-methoxyphenyl)-3-[2-fluoro-6-(trifluoromethyl)benzyl]-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino}butyrate structure](https://image.chemsrc.com/caspic/440/1092070-97-7.png)
| 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoic acid |
| 4-({(1R)-2-[5-(2-Fluoro-3-methoxyphenyl)-3-[2-fluoro-6-(trifluoromethyl)benzyl]-4-methyl-2,6-dioxo-3,6-dihydro-1(2H)-pyrimidinyl]-1-phenylethyl}amino)butanoic acid |
| Butanoic acid, 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-3,6-dihydro-4-methyl-2,6-dioxo-1(2H)-pyrimidinyl]-1-phenylethyl]amino]- |
| Elagolix |